Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

mesothelioma

- PMLiVE

Merck & Co, Ridgeback Biotherapeutics’ COVID-19 drug shows early promise

Molnupiravir led to a faster decrease in infectious virus among participants with early COVID-19

- PMLiVE

Merck & Co to help produce J&J’s COVID-19 vaccine in the US

Company has signed agreements to bolster vaccine manufacturing capacity

- PMLiVE

MSD withdraws Keytruda’s US indication for small cell lung cancer

Checkpoint inhibitor gained accelerated approval in 2019

- PMLiVE

Merck to acquire Pandion Therapeutics for $1.85bn

Merck will gain a pipeline of immune modulators targeting autoimmune diseases

- PMLiVE

AZ/Merck & Co’s PARP inhibitor Lynparza scores trial win in early breast cancer

Trial halted early after crossing superiority boundary for the primary endpoint of invasive disease-free survival

- PMLiVE

BMS links up with Molecular Templates for oncology research collaboration

Deal could be worth up to $1.3bn in milestone payments

- PMLiVE

New survival data for Merck, Eisai’s Keytruda/Lenvima combination shows promise in kidney cancer

Data presented at the virtual American Society of Clinical Oncology’s Genitourinary Cancers Symposium

- PMLiVE

BMS and Exelixis’ Opdivo/Cabometyx shows continued benefit in kidney cancer

Combination also demonstrated benefit in sarcomatoid subgroup with poor prognoses

- PMLiVE

FDA approves BMS’ blood cancer CAR T therapy after delay

The FDA's approval of Breyanzi came a year after the start of the review

- PMLiVE

Merck’s CEO Kenneth Frazier to retire after ten years in the role

Frazier is handing the reins over to current Merck CFO Robert Davis

- PMLiVE

Merck ends its COVID-19 vaccine programme after disappointing early trial results

Immune responses were inferior to levels observed in recovered COVID-19 patients

- PMLiVE

BMS gains FDA approval for second Opdivo combo in kidney cancer

BMS' Opdivo/Yervoy regimen was its first combo to be approved for advanced renal cell carcinoma

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links